Sanpower to Buy U.S. Cancer-Drug Maker for $820 million
(Beijing) — Sanpower Group Co. Ltd. has agreed to buy a U.S. maker of cancer vaccines for $820 million, marking the conglomerate’s largest move to date into the global industry for precision medicines.
The purchase is one of the largest-ever of an overseas drugmaker by a Chinese company. It will see Sanpower buy Dendreon, the U.S.-based cancer business of Canada’s Valeant Pharmaceuticals International Inc., Sanpower said in a statement on Tuesday.
- 1China Asks Banks to Assess Credit Risks Linked to Firms Active in Overseas Deals
- 2Beijing Is Soaking Wet
- 3Authorities Investigate Claims of Cadmium-Laced Wheat From Central China
- 4Weibo and Other Websites Barred From Video Streaming by Authority
- 5Real Estate Tycoon Removed as Political Adviser Over Bribery Allegation